Director and 10% Owner Sells $489K in Atara Biotherapeutics Stock
summarizeZusammenfassung
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
check_boxSchlusselereignisse
-
Insider Sale
James Huang, a Director and 10% owner, disposed of 80,554 shares of Atara Biotherapeutics common stock.
-
Significant Value
The sale amounted to $489,019, a substantial transaction for the company.
-
Transaction Price
Shares were sold at a weighted average price of $6.07 on January 12, 2026, compared to the current stock price of $4.58.
auto_awesomeAnalyse
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
Zum Zeitpunkt dieser Einreichung wurde ATRA bei 4,58 $ gehandelt an der NASDAQ im Sektor Life Sciences, bei einer Marktkapitalisierung von rund 32,2 Mio. $. Die 52-Wochen-Handelsspanne lag zwischen 4,25 $ und 19,15 $. Diese Einreichung wurde mit negativer Marktstimmung und einem Wichtigkeitsscore von 8 von 10 bewertet.